drugset / Trial / NCT02350959

Adverse Plaque Characteristics in CCTA and TVC Imaging

NCT02350959 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The present study is intended to assess the vulnerability of plaques seen on CCTA by means of TVC Imaging System and to make comparisons between plaques with adverse plaque characteristics and ones without adverse plaque characteristics in terms of plaque volume and lipid core contents.

Timeline

Start
2015-01
Primary completion
2016-01
Completion
2017-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 10 mg —
Subject Atorvastatin Small molecule 40 mg —

Indications

No indication recorded.